Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany

M.B. and R.E.: Writing manuscript, which included literature research. A.H.: reviewed the manuscript. M.B. and R.E.: Figures.

R.E. has received honoraria from Roche, Novartis, Pfizer, Mindpeak, AstraZeneca, and Eisai, reimbursement of travelling expenses from BioNTech, and research funding from NanoString Technologies, Cepheid, BioNTech, Gilead, and Zytomed Systems. A.H. has received honoraria from Bristol-Myers Sqibb, MSD, Roche, AstraZeneca, Boehringer Ingelheim, Abbvie, Janssen-Cilag and Ipsen, and research funding from Cepheid, BioNTech AG, Roche, Janssen-Cilag, NanoString Technologies and AstraZeneca. Moreover, he has acted as consulting/advisory role for Bristol-Myers Sqibb, MSD, Roche, Cepheid, Qiagen, Janssen-Cilag, AstraZeneca, Ipsen, NanoString Technologies (also expert testimony), Illumina, 3DHISTECH, Diaceutics. The remaining authors declares no conflict of interest.

Reprints: Ramona Erber, MD, Ms. PD Dr med, Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nürnberg (FAU), Comprehensive Cancer Center Erlangen-EMN, Krankenhausstraße 8-10, 91054 Erlangen, Bavaria, Germany (e-mail: [email protected]).